Cart
sales@molnova.com
M2I-1
CAS No. 312271-03-7
M2I-1 ( Mad2 inhibitor 1 )
Catalog No. M13998 CAS No. 312271-03-7
The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 58 | In Stock |
|
| 5MG | 110 | In Stock |
|
| 10MG | 178 | In Stock |
|
| 25MG | 410 | In Stock |
|
| 50MG | 605 | In Stock |
|
| 100MG | 860 | In Stock |
|
| 500MG | 1728 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameM2I-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionThe first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.
-
DescriptionThe first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2; disturbs conformational dynamics of Mad2 critical for complex formation with Cdc20, weakens the spindle assembly checkpoint (SAC) response.
-
SynonymsMad2 inhibitor 1
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorOthers
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number312271-03-7
-
Formula Weight404.48
-
Molecular FormulaC19H24N4O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESO=C(/C(C(N1)=O)=C\C2=CC=C(N(CC(C)C)CC(C)C)C([N+]([O-])=O)=C2)NC1=S
-
Chemical Name4,6(1H,5H)-Pyrimidinedione, 5-[[4-[bis(2-methylpropyl)amino]-3-nitrophenyl]methylene]dihydro-2-thioxo-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kastl J, et al. ACS Chem Biol. 2015 Jul 17;10(7):1661-6.
molnova catalog
related products
-
Cdc7 inhibitor 7c
A highly potent, selective and time-dependent Cdc7 kinase inhibitor with IC50 of 0.7 nM with slow dissociation property, with 200-fold and >14,000-fold selectivity over CDK2 and ROCK1, respectively.
-
Roscovitine
A potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively.
-
Riviciclib
A novel potent CDK inhibitor with IC50 of 79 nM, 63 nM and 20 nM for Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, respectively.
